Testing a new treatment for high-risk colon cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment approach for people with certain high-risk colon cancers (stage II or III in the upper colon) after surgery. It aims to see if adding a study drug can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colon cancer that is stage III or high-risk stage II, and it must be located in the upper part of the colon (at least 12 cm from the anus).
- You need to have a sample of your tumor preserved in paraffin (FFPE) available for testing.
- You must be well enough to do daily activities (ECOG score 0 or 1).
- You cannot have had any chemotherapy or radiation before your surgery.
- You cannot have had another cancer in the past 5 years (except for some skin cancers or very early cancers).
- You must be willing to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This trial studies how to find tiny hidden cancer cells after stage III colon cancer surgery using a blood test. If the blood test shows tumor DNA, you may get additional treatment to lower the chance of cancer coming back.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
Hear when a new Colon Cancer Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.